<span item_type="fundamental" item_id="2df771f48056e15f15bb80e0a4bec7de" counter_id="ST/US/SCND" env="prod"></span><span item_type="announcement" item_id="584627924354669313" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1.404 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.34.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.545 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Benchtop Laboratory Equipment</strong>: Revenue for the three months ended September 30, 2025, was $1,068,300, an increase from $881,900 in the same period in 2024. For the nine months ended September 30, 2025, revenue was $2,734,300, up from $2,380,600 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li><li><strong>Bioprocessing Systems</strong>: Revenue for the three months ended September 30, 2025, was $335,700, down from $452,500 in the same period in 2024. For the nine months ended September 30, 2025, revenue was $692,800, down from $1,134,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Loss from Operations</strong>: For the three months ended September 30, 2025, the loss from operations was $1,522,300, compared to $1,565,800 in 2024. For the nine months ended September 30, 2025, the loss was $5,434,700, compared to $5,685,800 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li><li><strong>Gross Profit</strong>: The gross profit percentage for the three months ended September 30, 2025, was 45.5%, down from 51.0% in 2024. For the nine months ended September 30, 2025, it was 39.8%, down from 44.1% in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the nine months ended September 30, 2025, net cash used in operating activities was - $4,390,700, compared to - $4,186,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: For the nine months ended September 30, 2025, net cash provided by investing activities was $2,444,300, compared to $2,429,900 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Gain on Sale of Genie Product Line</strong>: The company recorded a gain of $5,263,400 from the sale of the Genie product line in August 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to focus on the Bioprocessing Systems Operations, despite the current start-up stage and ongoing cash outflows. The sale of the Genie product line is expected to provide sufficient cash flow for at least one year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company completed the sale of its Genie Division, which is expected to streamline operations and focus resources on core business areas.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/87802/000165495425013308/scnd_10q.htm"></span></li></ul>

Scientific Industries, Inc. | 10-Q: FY2025 Q3 Revenue: USD 1.404 M